Instil Bio reports Q4 net loss $1.99/share; ends ITIL-306 trial, closes UK facility

Instil Bio, Inc.

Cash and investments of $175.0M as of Dec 31, 2023, down from $260.9M a year earlier; runway expected beyond 2026.
Q4 2023 net loss $1.99/share (GAAP), $1.26/share non-GAAP; full year net loss $24.00/share.
R&D expenses fell to $2.0M in Q4 2023 from $20.7M in Q4 2022; restructuring/impairment charges totaled $72.0M for the year.
Strategic collaboration announced for FRα-CoStAR TIL in NSCLC in China; ITIL-306 clinical trial stopped.
Closed UK manufacturing facility; management exploring in-licensing/acquisition of novel therapies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Instil Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-24-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.